DBV Technologies S.A. logo
DBV Technologies S.A. DBVT
$ 21.71 0.46%

Quarterly report 2025-Q2
added 07-29-2025

report update icon

DBV Technologies S.A. Balance Sheet 2011-2026 | DBVT

Annual Balance Sheet DBV Technologies S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-25.5 M -136 M -206 M -73.8 M -191 M -170 M -119 M -133 M -252 M -318 M -110 M -37.9 M -37.6 M -10.7 M

Long Term Debt

6.3 M 4.53 M 1.13 M 510 K 1.27 M 721 K 1.28 M 1.82 M 4.05 M 4.69 M 3.89 M 1.32 M 377 K 621 K

Long Term Debt Current

654 K 1.14 M 1.89 M 3 M 3.71 M - - - - - - - - -

Total Non Current Liabilities

7.14 M 5.46 M 22.5 M 16.1 M 14 M 21.8 M 6.92 M 12 M 15.6 M 5.18 M 4.42 M 1.61 M 632 K 741 K

Total Current Liabilities

31.1 M 37.3 M 29.5 M 31.4 M 52.7 M - - - - - - - - -

Total Liabilities

38.3 M 42.8 M 52.1 M 47.4 M 66.8 M 69.9 M 50.5 M 47.9 M 44.7 M 21.2 M 9.97 M 5.84 M 3.8 M 4.01 M

Deferred Revenue

- - - - - 3.2 M 4.36 M 2.79 M 3.25 M 791 K 1.05 M 794 K 127 K -

Retained Earnings

-286 M -239 M -260 M -259 M -959 M -154 M -166 M -148 M -115 M -44.7 M -24 M -19.3 M -13 M -7.24 M

Total Assets

65.7 M 183 M 247 M 147 M 272 M 241 M 172 M 178 M 288 M 343 M 125 M 46.2 M 43 M 15.7 M

Cash and Cash Equivalents

32.5 M 141 M 209 M 77.3 M 196 M 193 M - - - - - - - -

Book Value

27.4 M 140 M 194 M 99.3 M 205 M 172 M 121 M 130 M 243 M 322 M 115 M 40.4 M 39.2 M 11.7 M

Total Shareholders Equity

27.4 M 140 M 194 M 99.3 M 205 M 193 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet DBV Technologies S.A.

2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

6.7 M 6.52 M 7.04 M 6.78 M 6.79 M 94 K 187 K 680 K 1.13 M 1.42 M - 2.27 M 7.15 M 8.3 M 9.16 M 9.53 M 1.27 M 10.5 M 10.5 M 10.5 M 648 K - - - 2.84 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

7.78 M 7.3 M 8.11 M 7.71 M 7.76 M 14.3 M 19.9 M 21.1 M 22.5 M 7.67 M - 9.49 M 16.1 M 20.2 M 18.9 M 13.4 M 14 M 14 M 14 M 14 M 24.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

57.2 M 47.7 M 39 M 35.1 M 34.2 M 45.8 M 53.3 M 53.8 M 52.1 M 36.1 M - 35.5 M 47.4 M 54 M 57.6 M 52.2 M 66.8 M 66.8 M 66.8 M 66.8 M 78.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-315 M -313 M -263 M -233 M -266 M -228 M -211 M -280 M -260 M -220 M - -275 M -259 M -245 M -221 M -988 M -959 M -959 M -959 M -959 M -799 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

143 M 50.6 M 93.1 M 114 M 146 M 190 M 218 M 233 M 247 M 248 M - 118 M 147 M 171 M 201 M 221 M 272 M 272 M 272 M 272 M 272 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

103 M 13 M 46.4 M 66.2 M 102 M 149 M 174 M 209 M 209 M 213 M 248 M 74.1 M 77.3 M 98.2 M 125 M 152 M 196 M 196 M 196 M 196 M 193 M - - - 141 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

86.2 M 2.87 M 54 M 79.1 M 112 M 144 M 164 M 179 M 194 M 212 M - 82.1 M 99.3 M 117 M 143 M 169 M 205 M 205 M 205 M 205 M 193 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

86.2 M 2.87 M 54 M 79.1 M 112 M 144 M 164 M 179 M 194 M 212 M 244 M 82.1 M 99.3 M 117 M 143 M 169 M 205 M 205 M 205 M 205 M 193 M - - - 139 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of DBV Technologies S.A., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 18.24 -1.41 % $ 2.68 B usaUSA
Amgen Amgen
AMGN
$ 344.45 0.75 % $ 185 B usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 73.14 5.5 % $ 9.78 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Biogen Biogen
BIIB
$ 178.43 -0.81 % $ 26 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.7 3.85 % $ 17 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Adagene Adagene
ADAG
$ 2.87 4.36 % $ 162 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.11 -2.05 % $ 7.48 B australiaAustralia
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Burford Capital Limited Burford Capital Limited
BUR
$ 9.77 0.83 % $ 1.59 B britainBritain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.39 -1.42 % $ 261 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 222.86 -1.43 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.12 2.74 % $ 8.96 B israelIsrael
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 109.1 -4.09 % $ 27.2 B germanyGermany
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.39 1.09 % $ 355 M britainBritain
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.75 -0.29 % $ 83.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.85 0.54 % $ 166 M israelIsrael
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.11 3.14 % $ 4.36 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 6.64 0.91 % $ 1.37 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 27.95 1.19 % $ 2.3 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands